Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Alan Meds vs Framework

Alan Meds
Graded #98

Higher grade

vs+19.499999999999993
Framework
Graded #485

Lower grade

The verdict

Alan Meds takes it — 71.1/100 to 51.6/100.

Alan Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth platform offering compounded semaglutide and tirzepatide with multiple administration formats including microdosing and oral options.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAlan Meds +27
72
45
Dose & formulationAlan Meds +35
75
40
Clinical oversightAlan Meds +10
82
72
Labs & monitoringAlan Meds +1
53
52
FulfillmentAlan Meds +21
78
57
Contract termsAlan Meds +14
55
41
Alan Meds · left barFramework · right bar

The numbers

MetricAlan MedsFramework
WeighScore71.1/10051.6/100
GradeCC
Scorecard rank#98#485
Semaglutide$158/mo (compounded)Not disclosed
Tirzepatide$295/mo (compounded)Not disclosed
Coverage46 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Alan Meds

Graded #98 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access
  • Multiple administration formats

Where it loses points

  • Limited public information on program details
Framework

Graded #485 · C

Strengths

  • The compounding pharmacy partner is named, which most of this field does not do
  • Treatment selection is doctor-guided rather than a fixed product menu
  • US-licensed clinicians and a 503A pharmacy pathway

Where it loses points

  • No monthly medication price is published: the tirzepatide and semaglutide pages carry no price at all, and the homepage advertises a per-week figure for 'GLP-1s' generally rather than a rate for either drug
  • The only drug-specific prices anywhere on the site sit on a legacy page — semaglutide at $349 per three months and tirzepatide at $549 per three months
  • A '$75/month with 3-month package' figure is footnoted as a promotion for new GLP-1 users only
  • Different landing pages advertise different per-week rates, $25 on one and $19 on another
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard